anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a makeup cosmetic having excellent finish characteristics such as effects on impartment of a natural glossy feeling and a change of fine wrinkles into an inconspicuous state when applied to skin and excellent in smooth application feel by including a hexagonal platy aluminum oxide and an organic powder and/or a bright powder. SOLUTION: This makeup cosmetic is obtained by including (A) a hexagonal platy aluminum oxide, (B) an organic powder and/or (C) a bright powder. The average particle diameter of the ingredient A is preferably 0.5-20 μm and the average flakiness (aspect ratio) thereof is preferably 5-40. The crystal structure is preferably α. For example, the ingredient B is a nylon powder and the average particle diameter is preferably 1-35 μm. The reflectance thereof is preferably 1.3-1.7. For example, the ingredient C is a boron nitride powder and the average particle diameter is preferably 5-100 μm. The contents of the ingredients in the makeup cosmetic are preferably 0.1-50 wt.% of the ingredient A, 0.1-10 wt.% of the ingredient B and 0.1-20 wt.% of the ingredient C.
Bridging the gap between genotype and phenotype in GWAS studies is challenging. A multitude of genetic variants have been associated with immune-related diseases, including cancer, yet the interpretability of most variants remains low. Here, we investigate the quantitative components in the T cell receptor (TCR) repertoire, the frequency of clusters of TCR sequences predicted to have common antigen specificity, to interpret the genetic associations of diverse human diseases. We first developed a statistical model to predict the TCR components using variants in the TRB and HLA loci. Applying this model to over 300,000 individuals in the UK Biobank data, we identified 2309 associations between TCR abundances and various immune diseases. TCR clusters predicted to be pathogenic for autoimmune diseases were significantly enriched for predicted autoantigen-specificity. Moreover, four TCR clusters were associated with better outcomes in distinct cancers, where conventional GWAS cannot identify any significant locus. Collectively, our results highlight the integral role of adaptive immune responses in explaining the associations between genotype and phenotype.
They were as follows: being between 3 and 9 months of age, being full-term, had no complications during delivery. Infants that presented any type of sensory or motor disorder were excluded.
Outbreaks caused by vancomycin-resistant enterococci that transcend jurisdictional boundaries are occurring worldwide. This study focused on a vancomycin-resistant enterococcus outbreak that occurred between 2018 and 2021 across two cities in Hiroshima, Japan. The study involved genetic and phylogenetic analyses using whole-genome sequencing of 103 isolates of vancomycin-resistant enterococci to identify the source and transmission routes of the outbreak. Phylogenetic analysis was performed using core genome multilocus sequence typing and core single-nucleotide polymorphisms; infection routes between hospitals were inferred using BadTrIP. The outbreak was caused by Enterococcus faecium sequence type (ST) 80 carrying the vanA plasmid, which was derived from strain A10290 isolated in India. Of the 103 isolates, 93 were E. faecium ST80 transmitted across hospitals. The circular vanA plasmid of the Hiroshima isolates was similar to the vanA plasmid of strain A10290 and transferred from E. faecium ST80 to other STs of E. faecium and other Enterococcus species by conjugation. The inferred transmission routes across hospitals suggest the existence of a central hospital serving as a hub, propagating vancomycin-resistant enterococci to multiple hospitals. Our study highlights the importance of early intervention at the key central hospital to prevent the spread of the infection to small medical facilities, such as nursing homes, with limited medical resources and a high number of vulnerable individuals.
The invention relates to derivatives of the general formulae (I) and (II) to processes for the production thereof, to pharmaceutical preparations containing said compounds and/or physiologically compatible salts or solvates or prodrugs which can be produced therefrom as well as to the pharmaceutical use of said compounds, the salts or solvates thereof as adenosine receptor antagonists, in particular for the treatment of neurodegenerative disorders, e.g. stroke, amylotrophic lateral sclerosis, dementia, Alzheimer's disease, Parkinson's disease, ischemia/reperfusion injury, inflammation, and/or neurological disorder. The blockade of adenosine receptors could also be useful for other indications regarding the metabolism, e.g. diabetic retinopathy, diabetes mellitus, hyperbaric oxygen - induced retinopathy and/or obesity. Applications could also be the treatment of allergic diseases and autoimmune diseases, including mast cell degranulation, asthma, bronchoconstriction, pulmonary fibrosis, inflammatory or obstructive airways disease and/or chronic obstructive pulmonary disease (COPD). In addition, they could be used to treat cancer. The diseases associated with adenosine receptors are also diabetes, diarrhea, inflammatory bowel disease and/or gastrointestinal tract disorders. Adenosine receptor antagonists could be effective for treating a hepatic disease or condition for reducing fat deposition in the liver or fibrosis of the liver. The use of compounds of general formulae I or II can be associated with many applications e.g., scleroderm arthritis, atherosclerosis, urticaria, myocardial infarction, myocardial reperfusion after ischemia, vasodilation, hypertension, hypersensitivity, myocardial ischemia, heart attack and/or retinopathy of prematurity.
The ocular fundus is the only part of the human body that can directly see the blood vessel microcirculation and nerve tissue. Through various imaging tests, including Color Fundus Photograph (CFP), Optical Coherence Tomography (OCT), Fluorescein Fundus Angiography (FFA) and Indocyanine Green Angiography (ICGA), etc., it is possible to statically overview or dynamically observe the retina and choroid, the condition of blood vessels and nerves, and comprehensive diagnosis of the disease. The screening, interpreting and accurate diagnosis of ocular fundus diseases are crucial for disease prevention, control and precise treatment. However, due to the variety of fundus examination methods, and the complexity and professionalism of the examination, there is a lack of fundus specialists who have sufficient clinical experience and knowledge to interpret fundus examinations. With the continuous development of artificial intelligence (AI) in diagnosing fundus diseases, various modalities of imaging examination methods are gradually applied to the development of fundus disease diagnosis systems. Moreover, medical images often come with corresponding reports, which are mostly generated by clinicians' or radiologists' experience.

Here, we are establishing a fundus disease diagnosis and report-generating system based on cross-modal ocular fundus imaging examinations, and fundus lesions were visualized at the same time. Multi-center data verification will also be conducted. The results of the research will assist in fundus lesions diagnosis and imaging reports generation. We hope this could popularize more complex fundus imaging examination methods to society, and help improve the early diagnosis and treatment of fundus lesions that cause blindness.
A protective agent of superactive multicellular growth factor sPL, a preparation method and application thereof, relating to a protective agent of the cell growth factor and a preparation method and application thereof. The method aims to solve the problems that the sPL is unstable and insoluble components are separated out after being placed for a long time and subjected to temperature change or vibration. The protective agent comprises a solution A and a solution B; the A liquid comprises phosphatidylethanolamine, phosphatidylinositol, polyvinylpyrrolidone, sucrose fatty acid ester and ethanol solution; the solution B comprises xanthan gum, paloxamer-188, sodium alginate, heparin sodium and purified water. The method comprises the following steps: and adding the solution A into the solution B, and stirring until the solution A is in a uniform state to obtain the protective agent. The protecting agent has a protecting effect on sPL with various complex components, the sPL liquid added with the protecting agent is in a uniform state, no obvious precipitate is separated out, and the stability of the sPL liquid is not influenced by temperature change, transportation vibration and time. The invention is used for protecting the superactive multicellular growth factor sPL.
Patients receive ONC201 PO on days 1, 8, 15, and 22 and paclitaxel IV over 1 hour on days 2, 9, and 16. Cycles repeat every 28 days in the absence disease progression or unacceptable toxicity. If paclitaxel must be stopped for any reason, patients may continue on ONC201 alone.
Cardiovascular disease (CVD) is the leading cause of mortality in the U.S, and aging is the largest risk factor for vascular diseases. Both male and female adults have increased risk for CVD as they age. For postmenopausal women, this risk is particularly elevated due to the loss of the protective effect of estrogen. It is evident that nutrition plays a crucial role in prevention of chronic diseases such as heart disease, stroke and cancer. Scientific evidence shows that high intake of plant-based food lowers the risk of CVD and many other chronic diseases.

Polyphenolic compounds in fruits and nuts have been the focus of extensive research regarding their potential to reduce risk for a number of chronic diseases. However, fruits and nuts vary largely in the type and amounts of phytonutrients they provide. Mango (Mangifera Idica L.), a commonly cultivated fruit worldwide, is rich in polyphenolic compounds such as gallic acid, mangiferin, quercetin glycosides, ferulic acid, and hydroxybenzoic acid. Many of those bioactive compounds have been found to have anti-diabetic and anti-inflammatory effects in cell models. For instance, mangiferin has been proved to effectively reducing glucose-induced endoplasmic reticulum stress by inhibiting IREα phosphorylation and ROS production in endothelial cells. However, it is unknown if the phytonutrients in mango will demonstrate a similar impact in humans. Therefore, the overall objective of this study is to investigate the effects of acute mango intake on blood pressure and blood glucose.
Controllable device comprising a porous matrix, such as a micro-porous membrane, and a gel layer which is swellable at ambient temperature. The pores are produced in the membrane by etching and high energy particle bombardment, preferably with heavy ions . Controllable device comprising a porous matrix, such as a micro-porous membrane, and a gel layer which is swellable at ambient temperature. The pores are produced in the membrane by etching and high energy particle bombardment, preferably with heavy ions . The matrix consists of, or is coated with, the same material as the outer surface of the swellable layer. An AC or DC voltage is applied to electro-thermally or electro-osmotically control of the pores. The electrolytic region on both sides of the matrix are separated from each other and electrically insulated.  Cell (1) has a thermally or chemically responsive porous membrane, such as microporous membrane (2) lined with a glucose responsive gel possesses at least one pore (3), and typically many, of 10-1000 nm diameter. The cell is thermostatically jacketed , and contains aqueous glucose solution as electrolyte. In each of the chambers separated by the membrane (2) are immersed electrodes (7) which are preferably non-polarize Ag/AgCl, and to which are connected a source of AC or DC EMF, leading to a current flow through the pore(s) (3) and producing an electro-osmotic pressure acting from outside (6) to inside (5), or vice versa. The effect may alternatively, or in addition, simultaneously cause a temperature change in the pore(s).
BACKGROUND: An analytical benchmark for high-sensitivity cardiac troponin (hs-cTn) assays is to achieve a coefficient of variation (CV) of ≤ 10.0 % at the 99th percentile upper reference limit (URL) used for the diagnosis of myocardial infarction. Few prospective multicenter studies have evaluated assay imprecision and none have determined precision at the female URL which is lower than the male URL for all cardiac troponin assays.
METHODS: Human serum and plasma matrix samples were constructed to yield hs-cTn concentrations near the female URLs for the Abbott, Beckman, Roche, and Siemens hs-cTn assays. These materials were sent (on dry ice) to 35 Canadian hospital laboratories (n = 64 instruments evaluated) participating in a larger clinical trial, with instructions for storage, handling, and monthly testing over one year. The mean concentration, standard deviation, and CV for each instrument type and an overall pooled CV for each manufacturer were calculated.
RESULTS: The CVs for all individual instruments and overall were ≤ 10.0 % for two manufacturers (Abbott CVpooled = 6.3 % and Beckman CVpooled = 7.0 %). One of four Siemens Atellica instruments yielded a CV > 10.0 % (CVpooled = 7.7 %), whereas 15 of 41 Roche instruments yielded CVs > 10.0 % at the female URL of 9 ng/L used worldwide (6 cobas e411, 1 cobas e601, 4 cobas e602, and 4 cobas e801) (CVpooled = 11.7 %). Four Roche instruments also yielded CVs > 10.0 % near the female URL of 14 ng/L used in the United States (CVpooled = 8.5 %).
CONCLUSIONS: The number of instruments achieving a CV ≤ 10.0 % at the female 99th-percentile URL varies by manufacturer and by instrument. Monitoring assay precision at the female URL is necessary for some assays to ensure optimal use of this threshold in clinical practice.
Cysteine methyl ester hydrochloride is prepared by reacting cysteine hydrochloride with at least 4 molecular equivalents of methyl alcohol in the presence of hydrochloric acid.  In an example, the reaction is effected at the boiling point while passing hydrogen chloride through the mixture.  The product can be purified by recrystallization from methyl alcohol, from a mixture of methyl alcohol with dry ethyl acetate or dry ethyl ether or from dioxane, either mixed with a small amount of water alone or with a small amount of water and methanol. The free base can be liberated and converted to the neutral sulphate.ALSO:The invention comprises a therapeutic composition consisting of a buffered aqueous solution of cysteine methyl ester hydrochloride.  A suitable aqueous buffer solution is one which by itself has a pH of 7, such as is obtained by dissolving citric acid and disodium phosphate in water.  The preparation of the pure ester-salt is described (see Group IV (b)).
The invention relates to a peptide derived from neurotensin receptor 3 (NTSR3), and to the use thereof in the treatment of psychiatric diseases. The present invention particularly relates to the use of this peptide for producing a drug, such as an antidepressant. The peptide of the invention is characterised in that the sequence thereof is the attached SEQ ID n°2. The present invention can be used in the fields of the pharmaceutical industry and particularly in the field of drug development for treating psychiatric diseases. The present invention can also be used in the development of a novel antidepressant. It can also be used, for example, in the treatment of pain and inflammations.
BACKGROUND: We assessed the influence of prior non-vitamin K antagonist (NOAC) use on stroke outcomes after endovascular treatment (EVT) in patients at a high risk of stroke based on their pre-stroke CHA2DS2-VASc score, and compared them with those who did not use any antithrombotic (NAU) or antiplatelet (APT) agents.
METHODS: Data were collected from a multicenter database comprising consecutive acute ischemic stroke patients who underwent EVT during a span of 103 months. We evaluated pre-stroke CHA2DS2-VASc scores in enrolled patients and measured instances of successful reperfusion and symptomatic hemorrhagic transformation (SHT) following EVT as the main outcome measures.
RESULTS: Among 12 807 patients with acute ischemic stroke, 3765 (29.4%) had a history of atrial fibrillation. Of these, 418 patients with CHA2DS2-VASc scores ≥2 received EVT alone. The prior NOAC group showed higher successful reperfusion rates compared with the prior NAU and APT groups (p=0.04). Multivariate analysis revealed that prior NOAC use increased the likelihood of successful reperfusion after EVT (OR [95% CI] 2.54 [1.34 to 4.83], p=0.004) and improved stroke outcomes, while the prior APT group did not. Furthermore, the prior NOAC use group was not associated with SHT after EVT. Propensity score matching confirmed these findings.
CONCLUSION: Prior use of NOAC is associated with improved outcomes in high-risk stroke patients (pre-stroke CHA2DS2-VASc score ≥2) undergoing EVT.
The present invention is based on the use of electrical surface charge as a docking tool to bring charged lipid assemblies in the vicinity of a diseased, e.g. inflamed epithelium of the mucosa, or alternatively, to a normal epithelium, for executing a desired medical procedure. Thus, the present invention provides a method for selecting a medicament for a medical procedure has now been designed. The medical procedure is selected from treatment, for the healing of a disease or disorder of a mucosa, prophylaxis of a disease or disorder or a mucosa, or a combination of same. The method steps are based on the observation that there are differences in the attachment properties of charged lipid assemblies, such as liposomes, when examined in healthy or inflamed mucosal tissues. The invention also provides a kit making use of the method of the invention. Yet, the invention concerns a method and a medicament for the treatment or prevention of a disease or disorder of the gastrointestinal mucosa, as well as the use of charged lipid assemblies for obtaining said medicament, based on the principles of the differential adhesion of positively vs. negatively charged lipid assemblies to healthy and diseased mucosa, respectively.
INTRODUCTION: This study aimed to assess emergency nurses' perceived barriers toward engaging patients in serious illness conversations.
METHODS: Using a mixed-method (quant + QUAL) convergent design, we pooled data on the emergency nurses who underwent the End-of-Life Nursing Education Consortium training across 33 emergency departments. Data were extracted from the End-of-Life Nursing Education Consortium post-training questionnaire, comprising a 5-item survey and 1 open-ended question. Our quantitative analysis employed a cross-sectional design to assess the proportion of emergency nurses who report that they will encounter barriers in engaging seriously ill patients in serious illness conversations in the emergency department. Our qualitative analysis used conceptual content analysis to generate themes and meaning units of the perceived barriers and possible solutions toward having serious illness conversations in the emergency department.
RESULTS: A total of 2176 emergency nurses responded to the survey. Results from the quantitative analysis showed that 1473 (67.7%) emergency nurses reported that they will encounter barriers while engaging in serious illness conversations. Three thematic barriers-human factors, time constraints, and challenges in the emergency department work environment-emerged from the content analysis. Some of the subthemes included the perceived difficulty of serious illness conversations, delay in daily throughput, and lack of privacy in the emergency department. The potential solutions extracted included the need for continued training, the provision of dedicated emergency nurses to handle serious illness conversations, and the creation of dedicated spaces for serious illness conversations.
DISCUSSION: Emergency nurses may encounter barriers while engaging in serious illness conversations. Institutional-level policies may be required in creating a palliative care-friendly emergency department work environment.
HIV infection is known to cause profound and irreversible dysfunction of both innate and adaptive arms of the immune system. However, there is mounting evidence that early and aggressive treatment with antiretroviral drugs can prevent loss of immune cell function. In an attempt to further delineate the effect of early antiretroviral therapy (ART) on maintenance of immune cell function, we wish to recruit drug-naive HIV-infected patients who are either in early or chronic stage of infection. The study will require that patients undergo leukapheresis or research blood draw once before and several times after enrollment. Leukapheresis will be used in order to obtain sufficient cells to pursue the following objectives: delineating B cell response to CD4+T cell help, delineating the effect of ART on persistent HIV reservoirs in CD4+T cells of infected individuals, and delineating CD8+T cell-mediated suppression of viral replication and normalization of immune function, and characterizing natural killer (NK) function relative to HIV disease. The required number of mononuclear cells needed to perform these experiments can be easily and safely obtained using leukapheresis procedures in the Clinical Center Apheresis Unit. This protocol is specifically designed to conform to the requirements of the Apheresis Unit for donors to have leukapheresis procedures, but the protocol, by itself, is not an independent research study. Alternatively, whole blood draws may be used in cases where patients are unable to undergo leukapheresis. While this approach will limit extensive functional analyses, informative phenotypic and limited functional analyses can nonetheless be performed.
Droxidopa will be titrated over a 2-week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks. Then, the subject will start sugar pills.
Patient navigation will be rolled out at the clinic level (15 clinics). Referral orders will become available to participating clinics, with education and audit and feedback for providers. The study team will tailor patient navigation supports by clinic site for specifics on how the intervention is delivered.
In a recent stereotactic body radiation therapy animal model, radiation pneumonitis and radiation pulmonary fibrosis were observed at around 2 and 6 weeks, respectively. However, the molecular signature of this model remains unclear. This study aimed to examine the molecular characteristics at these two stages using RNA-seq analysis. Transcriptomic profiling revealed distinct transcriptional patterns for each stage. Inflammatory response and immune cell activation were involved in both stages. Cell cycle processes and response to type II interferons were observed during the inflammation stage. Extracellular matrix organization and immunoglobulin production were noted during the fibrosis stage. To investigate the impact of a 10 Gy difference on fibrosis progression, doses of 45, 55, and 65 Gy were tested. A dose of 65 Gy was selected and compared with 75 Gy. The 65 Gy dose induced inflammation and fibrosis as well as the 75 Gy dose, but with reduced lung damage, fewer inflammatory cells, and decreased collagen deposition, particularly during the inflammation stage. Transcriptomic analysis revealed significant overlap, but differences were observed and clarified in Gene Ontology and KEGG pathway analysis, potentially influenced by changes in interferon-gamma-mediated lipid metabolism. This suggests the suitability of 65 Gy for future preclinical basic and pharmaceutical research connected with radiation-induced lung injury.